The Role of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From RCC
Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).
Clinical Pearls
Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).
- About 20 years ago, subsequent cytoreductive nephrectomy and interferon demonstrated a survival advantage in patients with metastatic RCC
- Researchers and oncologists question whether cytoreductive nephrectomy should remain a part of the treatment approach in this space
- Several retrospective analyses have supported the current role of cytoreductive nephrectomy
- Patient selection bias prevents too much weight being placed on these retrospective studies
- Two prospective studies are underway, though it will be some time before those read out
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
